Marshall Wace’s Definium Therapeutics DFTX Stock Holding History

Marshall Wace’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.7M	Sell	1,200,825 -1,774,877	-60%	-$30.1M	0.02%	658
2025 Q4	$39.8M	Buy	2,975,702 +593,722	+25%	+$7.35M	0.04%	406
2025 Q3	$28.1M	Sell	2,381,980 -1,039,244	-30%	-$9.69M	0.03%	512
2025 Q2	$22.2M	Buy	3,421,224 +828,067	+32%	+$5.45M	0.03%	549
2025 Q1	$15.2M	Buy	2,593,157 +91,766	+4%	+$657K	0.02%	613
2024 Q4	$17.4M	Buy	2,501,391 +213,526	+9%	+$1.47M	0.02%	589
2024 Q3	$13M	Buy	2,287,865 +127,662	+6%	+$888K	0.02%	661
2024 Q2	$15.6M	Buy	2,160,203 +161,659	+8%	+$1.41M	0.02%	576
2024 Q1	$18.8M	Buy	+1,998,544	New	+$11.4M	0.03%	530
2023 Q4	–	Sell	-11,545	Closed	-$36.1K	–	2452
2023 Q3	$36.1K	Buy	+11,545	New	+$47.5K	﹤0.01%	2102

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace's DFTX Position: Q1 2026 in Review

Marshall Wace reduced its Definium Therapeutics (DFTX) stake by 60% in Q1 2026, selling an estimated $30.1M and leaving 1,200,825 shares worth $22.7M. The position accounts for 0.02% of the portfolio, ranked #658.

Marshall Wace first reported a position in DFTX in Q3 2023 and has held it in 10 quarters since. The position peaked at $39.8M in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Marshall Wace held 1,200,825 shares of Definium Therapeutics worth $22.7M as of Q1 2026.
Marshall Wace sold 1,774,877 Definium Therapeutics shares in Q1 2026, an estimated $30.1M.
Definium Therapeutics made up 0.02% of Marshall Wace's portfolio in Q1 2026, its #658 holding.
Marshall Wace first reported a position in Definium Therapeutics in Q3 2023 and has held it in 10 quarters since.
Marshall Wace's Definium Therapeutics position peaked at $39.8M in Q4 2025.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.